Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Posaconazole versus voriconazole for first-line treatment of invasive aspergillosis
2011-003938-14Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Feb 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in invasive aspergillosis (IA) and aspergillosis comparing Posaconazole arm with Voriconazole arm (2 arms). Primary endpoint: Global clinical response at Week 6. Started Feb 2013; status: completed.
02
Drugs
posaconazolevoriconazole
03
Conditions
invasive aspergillosis (IA)aspergillosis
Beyond the preview
Go deeper on 2011-003938-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003938-14.